Total
0
Shares
Mesoblast (ASX:MSB) - Managing Director & CEO, Silviu Itescu
Managing Director & CEO, Silviu Itescu
Source: Mesoblast
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • Mesoblast (MSB) has placed its shares in a trading halt before the weekend as it gears up to raise some fresh capital
  • The stem cell specialist has flagged a “proposed private placement to a targeted industry investor”
  • However, no further details of the capital raise have been revealed just yet
  • As it stands, Mesoblast shares will remain in a trading halt until Tuesday, March 2, unless Mesoblast releases the details of the raise before the
  • Mesoblast is busy developing stem-cell-based treatments for a range of complex inflammatory diseases
  • The company has several key drug candidates in third-phase clinical trials
  • Mesoblast shares last traded for $2.46 each on Thursday afternoon

Mesoblast (MSB) has placed its shares in a trading halt before the weekend as it gears up to raise some fresh capital.

While the details of the raise have not yet been announced, the stem cell specialist revealed that it will not be a conventional on-market capital raise; Mesoblast is planning a “proposed private placement to a targeted industry investor”.

It’s not clear just yet who this investor is or how much they plan to invest in Mesoblast.

As it stands, MSB shares will remain in a trading halt until Tuesday, March 2, unless Mesoblast releases the details of the raise before then.

Mesoblast is busy developing stem-cell-based treatments for a range of complex inflammatory diseases that are resistant to conventional standards of care.

The company’s range of third-phase product candidates includes its Remestemcel-L drug, which is being developed to treat acute graft-versus-host disease (acute GVHD) in children.

This is a rare condition in which the human body reject bone marrow transplants.

Remestemcel-L is also in third-phase trials for severe acute respiratory distress syndrome (ARDS) due to COVID-19 infections.

Essentially, ARDS is a type of respiratory failure that occurs when air sacs in the lungs fill with fluid and organs become deprived of oxygen. This condition is the leading cause of death from COVID-19.

On top of this, Mesoblast has its REVASCOR treatment in third-phase trials for chronic heart failure and MPC-06-ID treatment in third-phase trials for chronic lower back pain due to degenerative disc disease.

Shares in Mesoblast last traded for $2.46 each on Thursday afternoon.

MSB by the numbers
More From The Market Herald
ADX Energy (ASX:ADX) - Executive Chairman, Ian Tchacos

" ADX Energy (ASX:ADX) starts week in trading halt ahead of fundraise

ADX Energy (ADX) has started the week off in a trading halt, as it gears up to raise additional cash via a capital

" Cobram Estate Olives (ASX:CBO) to raise $50m for growth

Cobram Estate Olives (CBO) has announced a $50 million capital raise to support growth strategies in Australia and the United States.

" Equus Mining (ASX:EQE) enters trading halt following project acquisition

Equus Mining (EQE) has entered a trading halt regarding an upcoming capital raise.
icetana (ASX:ICE) - CEO & Managing Director, Matthew Macfarlane

" icetana (ASX:ICE) begins week in trading halt

Software company icetana (ICE) has begun the week in a trading halt while it plans the details of an upcoming capital raising.